Kirk Calhoun
Director/Board Member bij NANTHEALTH, INC.
Vermogen: 44 355 $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Patrick Soon-Shiong | M | 71 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 17 jaar |
Michael Valentino | M | 70 |
Adams Respiratory Therapeutics, Inc.
Adams Respiratory Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adams Respiratory Therapeutics, Inc. manufactures over-the-counter remedies for respiratory ailments. The company's products include Mucinex, Mucinex DM, Maximum Strength Mucinex, Mucinex DM, Mucinex D, and the Delsym. It is a subsidiary of Reckitt Benckiser Corp. Adams Respiratory Therapeutics is headquartered in Chester, NJ | 19 jaar |
Mark Silver | M | 53 | 11 jaar | |
Edward Lehner | M | 58 | 12 jaar | |
Leon Ekchian | M | 67 |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | 16 jaar |
Stephen Larson | M | 67 | 10 jaar | |
Charles Hunt | M | - | - | |
David Hayes | M | 69 |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | 10 jaar |
Ronda K. Dean | F | - | 16 jaar | |
Molly Kannan | F | 42 | 11 jaar | |
Michael Blaszyk | M | 71 | 9 jaar | |
Gary Balkema | M | 69 | 8 jaar | |
Jacob Kotzubei | M | 55 | 14 jaar | |
Mary Sigler | F | 69 | 14 jaar | |
Colin Kealey | M | - |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | - |
John Orth | M | 57 | 6 jaar | |
Eva Monica Kalawski | F | 69 | 10 jaar | |
Kevin Roy Harris | M | 55 | 12 jaar | |
Bob Casale | M | 65 | 8 jaar | |
Phil Norment | M | 64 | 10 jaar | |
Susan Overly | F | - | 16 jaar | |
R. Naseem | M | 57 | 1 jaar | |
Brandon Villery | M | - | - | |
Michael Burbach | M | 63 | 19 jaar | |
Court Carruthers | M | 51 | 10 jaar | |
Joanne Cotignola | F | - | 5 jaar | |
James Claussen | M | 51 | 22 jaar | |
Thomas Paschall | M | - |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | - |
Bruce Williams | M | 69 | 13 jaar | |
Lawrence Perkins | M | 47 | 1 jaar | |
Srini Sundarrajan | M | 52 | 5 jaar | |
Tiffany Avery | M | - | 5 jaar | |
Lillian Kimbell | F | - |
California State University Foundation
California State University Foundation Financial ConglomeratesFinance Part of The California State University, California State University Foundation is a university funding arm. The private company is based in San Bernardino, CA. | - |
Marc L. Harrison | M | - | - | |
Pratham Dear | M | - | 2 jaar | |
John Halloran | M | - | 1 jaar | |
James Nash | M | - | - | |
Ronald Barhorst | M | 67 |
California State University Foundation
California State University Foundation Financial ConglomeratesFinance Part of The California State University, California State University Foundation is a university funding arm. The private company is based in San Bernardino, CA. | - |
Michael Lucki | M | 67 |
California State University Foundation
California State University Foundation Financial ConglomeratesFinance Part of The California State University, California State University Foundation is a university funding arm. The private company is based in San Bernardino, CA. | - |
Bob Petrou | M | 52 | 6 jaar | |
Jorge Mariano Beristain | M | 54 | 2 jaar | |
Robert Sellers | M | - |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | - |
Elizabeth Dávila | F | 80 | - | |
Lodwrick Monroe Cook | M | 95 |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | - |
Joe A. Rose | M | 72 |
National Association of Corporate Directors (Virginia)
National Association of Corporate Directors (Virginia) Miscellaneous Commercial ServicesCommercial Services National Association of Corporate Directors provides online and print information services to directors of public companies. It offers in-boardroom education, evaluation, governance reviews, board composition and succession planning, board recruitment, ongoing advisory, insights, and analytics services. The company was founded in 1977 and is headquartered in Arlington, VA. | - |
John C. Molina | M | - |
California State University Foundation
California State University Foundation Financial ConglomeratesFinance Part of The California State University, California State University Foundation is a university funding arm. The private company is based in San Bernardino, CA. | - |
Aimee Weisner | F | 55 |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | 10 jaar |
Robert D. Kittredge | M | 77 |
California State University Foundation
California State University Foundation Financial ConglomeratesFinance Part of The California State University, California State University Foundation is a university funding arm. The private company is based in San Bernardino, CA. | - |
Steven Valentino | M | - | 7 jaar | |
James Hindman | M | 63 |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | 10 jaar |
Rodney Markin | M | 67 | 7 jaar | |
Thomas L. Long | M | - | 7 jaar | |
Gaddi Vasquez | M | 69 |
California State University Foundation
California State University Foundation Financial ConglomeratesFinance Part of The California State University, California State University Foundation is a university funding arm. The private company is based in San Bernardino, CA. | - |
Sarah Stoesz | F | - | - | |
Christopher M. DeGiorgio | M | - |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | 12 jaar |
Ian A. Cook | M | 64 |
NeuroSigma, Inc.
NeuroSigma, Inc. Medical SpecialtiesHealth Technology NeuroSigma, Inc. operates as a life sciences company which develops bioelectronic technologies to treat major neurological and neuropsychiatric disorders such as epilepsy and depression. Its non-invasive external trigeminal nerve stimulation system (eTNS) employs trigeminal nerve stimulation, or TNS, as adjunctive therapy for drug-resistant epilepsy and major depressive disorder. The company was founded by Leon Ekchian in March 2008 and is headquartered in Los Angeles, CA. | 15 jaar |
Vince Russell | M | - | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Noel F. Hall | M | - |
Aspreva Pharmaceuticals Corp.
Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | 7 jaar |
Denise McNairn | F | 56 | 5 jaar | |
John Q. Adams | M | 86 |
Adams Respiratory Therapeutics, Inc.
Adams Respiratory Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adams Respiratory Therapeutics, Inc. manufactures over-the-counter remedies for respiratory ailments. The company's products include Mucinex, Mucinex DM, Maximum Strength Mucinex, Mucinex DM, Mucinex D, and the Delsym. It is a subsidiary of Reckitt Benckiser Corp. Adams Respiratory Therapeutics is headquartered in Chester, NJ | - |
David P. Becker | M | 57 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY.
Adams Respiratory Therapeutics, Inc.
Adams Respiratory Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adams Respiratory Therapeutics, Inc. manufactures over-the-counter remedies for respiratory ailments. The company's products include Mucinex, Mucinex DM, Maximum Strength Mucinex, Mucinex DM, Mucinex D, and the Delsym. It is a subsidiary of Reckitt Benckiser Corp. Adams Respiratory Therapeutics is headquartered in Chester, NJ | 16 jaar |
Richard Glickman | M | 65 |
Aspreva Pharmaceuticals Corp.
Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | 5 jaar |
William Kimsey | M | 81 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | 9 jaar |
Kathleen Danenberg | F | 77 | 11 jaar | |
Lonnie Moulder | M | 66 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 1 jaar |
Ronald Allen Louks | M | 59 | - | |
Michael S. Sitrick | M | 76 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 9 jaar |
Natasha Giordano | F | 62 | 7 jaar | |
Nebojsa Janjic | M | 63 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 8 jaar |
Bruce Wendel | M | 70 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 jaar |
Gary Palmer | M | - | 2 jaar | |
Jason A. Leverone | M | 50 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 jaar |
Robert D. Jenison | M | 58 | 11 jaar | |
Jean-Francois Gimonet | M | - |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 3 jaar |
Deanna L. Wise | F | 55 | 3 jaar | |
Erich S. Schnaufer | M | 56 | 15 jaar | |
Richard C. Wyman | M | - |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | 6 jaar |
Mark Mozley | M | - | - | |
Mitchall G. Clark | M | 63 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 jaar |
Mark Burnett | M | 63 | 2 jaar | |
Justine Carlson | M | - | 8 jaar | |
Christine Cassiano | F | - |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL | 1 jaar |
Lisa Gopalakrishnan | F | 62 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 2 jaar |
Bob Watson | M | 67 | 2 jaar | |
David Michael Smith | M | 57 | 12 jaar | |
John Adams | M | 62 |
Adams Respiratory Therapeutics, Inc.
Adams Respiratory Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adams Respiratory Therapeutics, Inc. manufactures over-the-counter remedies for respiratory ailments. The company's products include Mucinex, Mucinex DM, Maximum Strength Mucinex, Mucinex DM, Mucinex D, and the Delsym. It is a subsidiary of Reckitt Benckiser Corp. Adams Respiratory Therapeutics is headquartered in Chester, NJ | 5 jaar |
Thomas Stankovich | M | 63 | 4 jaar | |
Michael Hayden | M | 72 |
Aspreva Pharmaceuticals Corp.
Aspreva Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Aspreva Pharmaceuticals Corp. manufactured pharmaceutical products. It offered therapeutic products, research equipment, and related services. The firm developed drugs for the treatment of cancer, infectious diseases, and immune disorders. The company was founded in 2001 and is headquartered in Victoria, Canada. | 5 jaar |
Roy Cecil Andersen | M | 76 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | 26 jaar |
Michael Arnold | M | 67 | 4 jaar | |
Leonard Shapiro | M | 96 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 9 jaar |
Stephen D. Nimer | M | 70 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 10 jaar |
David Chen | M | 76 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 13 jaar |
Paul A. Holt | M | 57 | 3 jaar | |
Mark L. Smith | M | 72 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | 3 jaar |
Ronald E. Pauli | M | 63 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL | 4 jaar |
Carlo Montagner | M | 56 |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 5 jaar |
Jeffrey Steven Silverman | M | - |
Abraxis BioScience, Inc. /Old/
Abraxis BioScience, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 1 jaar |
J. Paul Whitehead | M | 62 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | 6 jaar |
Corey Eagle | M | - |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | 10 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 88 | 88.00% |
Canada | 3 | 3.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Kirk Calhoun
- Persoonlijk netwerk